Edition:
United States

Aquinox Pharmaceuticals Inc (AQXP.OQ)

AQXP.OQ on NASDAQ Stock Exchange Global Market

10.08USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$10.08
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
19,191
52-wk High
$19.90
52-wk Low
$10.05

Summary

Name Age Since Current Position

David Main

50 2014 Co-Founder, President and Chief Executive Officer and Chairman of the Board

Kamran Alam

40 2011 Chief Financial Officer, Vice President - Finance

Lloyd Mackenzie

47 2013 Vice President - Technical Operations and Planning

David Mitchell

59 2014 Vice President - Global Regulatory Affairs & Quality Assurance

Barbara Troupin

48 2016 Chief Medical Officer, Vice President - Clinical Development

Robert Pelzer

63 2013 Lead Independent Director

Gary Bridger

52 2013 Director

Daniel Levitt

68 2008 Director

Richard Levy

59 2017 Director

Kelvin Neu

42 2017 Director

Sean Nolan

49 2015 Director

Todd Simpson

56 2014 Director

Biographies

Name Description

David Main

Mr. David J. Main is Co-Founder, President and Chief Executive Officer and Chairman of the Board of Aquinox pharmaceuticals, Inc., effective January 2014. From September 1996 to June 2005, Mr. Main held various positions at INEX Pharmaceuticals Corp., a biopharmaceutical company, serving as President and Chief Executive Officer from July 1999 to June 2005 and as Vice President, Corporate Development from September 1996 to July 1999. While President and Chief Executive Officer, Mr. Main led the transformation of INEX from a research driven to a product focused biopharmaceutical company, advancing product development to the NDA stage and securing several significant pharmaceutical partnerships and over $100 million in equity financings. From 1990 to 1996, Mr. Main held various positions at QLT Inc., a pharmaceutical company, most recently serving as Vice President. Mr. Main was formerly a licensed pharmacist at the Royal Columbian Hospital in New Westminster, B.C. Mr. Main holds a B.Sc. in Pharmacy and an M.B.A. from the University of British Columbia. Mr. Main previously served on the board of directors of LifeSciences BC, a non-profit industry association. Mr. Main also serves on the board of directors for BIOTECanada, a Canadian industry association, and Discovery Parks Trust, a not-for-profit association, and most recently, bio.org, a U.S. industry association.

Kamran Alam

Mr. Kamran Alam is Chief Financial Officer, Vice President - Finance of the Company since August 2011. From June 2010 to August 2011, Mr. Alam served as Senior Director, Business Development of Sirius Genomics Inc., a biotechnology company. From October 2008 to June 2010, Mr. Alam served as Director, Business Development of the Centre for Drug Research and Development, a drug development and commercialization center. From January 2007 to October 2008, Mr. Alam served as Senior Manager, Business Development of Angiotech Pharmaceuticals, Inc., a pharmaceutical company. From 2004 to 2007, Mr. Alam served as Manager, Business Development of AnorMED Inc., a chemistry-based biopharmaceutical company. From 1998 to 2000, Mr. Alam worked in the life sciences practice group of PriceWaterhouseCoopers LLP, a global accounting and auditing firm where he obtained his Chartered Accountant designation, and gained valuable experience in the financing, auditing and tax structuring of a number of biotechnology and technology companies. Mr. Alam holds a B.Sc. in Cell Biology and Genetics from the University of British Columbia and an M.B.A. in International Business and Strategy from the University of Victoria and is a Chartered Accountant.

Lloyd Mackenzie

Mr. Lloyd Mackenzie is Vice President, Technical Operations and Planning of the Company since May 2013 and prior to that had served as our Senior Director, Technical Operations since May 2008. From 2007 to 2008, Mr. Mackenzie served as a Research Scientist of Pharmaceutical Development at QLT. From 1999 to 2007, Mr. Mackenzie served as a Research Scientist of Inflazyme Pharmaceuticals Inc., a biotechnology company. Mr. Mackenzie is the author of 15 scientific publications and is an inventor on four patents. Mr. Mackenzie holds a B.Sc. in Chemistry and Biochemistry from Simon Fraser University

David Mitchell

David Mitchell is Vice President, Global Regulatory Affairs & Quality Assurance of the Company since December 2014. From November 2011 to November 2014, Mr. Mitchell served as director, global regulator lead—oncology at AbbVie, Inc., a global, research-based biopharmaceutical company. From August 2010 to November 2011, Mr. Mitchell served as director of regulatory affairs at Dendreon Corporation, a publicly-traded biopharmaceutical company. Additionally, he was responsible for building the Regulatory and Quality infrastructure at several small biotechnology companies in the United States. He presently serves on the Global Committee of The Food and Drug Law Institute where he provides advice on program and policy development in global food and drug law. Mr. Mitchell holds a M.Sc. degree in Bioscience Regulatory Affairs from The Johns Hopkins University and a BS in Chemistry degree from Mississippi College.

Barbara Troupin

Dr. Barbara Troupin, M.D., serves as Chief Medical Officer, Vice President - Clinical Development of the Company. From Aquinox's offices in San Bruno, California, Dr. Troupin will lead overall clinical and medical affairs strategies for Aquinox's ongoing programs as well as future development and potential commercialization plans. Dr. Troupin brings extensive clinical leadership experience from previous roles with Apricus Bioscience, Inc. and VIVUS, Inc. Dr. Troupin received her Doctorate in Medicine in 1995 from the University of Pennsylvania School of Medicine where she also completed her Master's in Business Administration, with an emphasis in health care management, from the Wharton School of Business.

Robert Pelzer

Mr. Robert E. Pelzer is Director of the Company since July 2013. From September 2008 to December 2013, Mr. Pelzer served as President of Novartis Corporation, a pharmaceutical company. From 2002 to 2008, Mr. Pelzer served as General Counsel at Novartis Pharma AG. Prior to 2002, Mr. Pelzer held various positions at DuPont, a chemical company, including serving as General Counsel and Senior Vice President at DuPont Pharmaceuticals from 1998 to 2001. Mr. Pelzer holds a B.A. in Commerce and an LL.B. from the University of Alberta. Mr. Pelzer previously served on the board of directors of Idenix Pharmaceuticals, Inc., a biotechnology company.

Gary Bridger

Mr. Gary J. Bridger, Ph.D. is Director of the Company since October 2013. Since January 2013, Dr. Bridger has served as the Executive Vice President of Research and Development of Xenon Pharmaceuticals Inc., a biopharmaceutical company. From June 2010 to June 2012, Dr. Bridger served as a partner at Venture West Capital Management, a venture capital firm. From November 2006 to December 2007, Dr. Bridger served as Senior Vice President of Research and Development of Genzyme Corporation, a biotechnology company, which was acquired by Sanofi, S.A. In June 1996, Dr. Bridger co-founded AnorMED Inc., a biopharmaceutical company, and was its Vice President of Research and Development and Chief Scientific Officer from 2000 until its acquisition by Genzyme in November 2006. Dr. Bridger currently serves on the board of directors of Alder BioPharmaceuticals, Inc. and on numerous private company boards of directors. Dr. Bridger holds a Ph.D. in Organic Chemistry from the University of Manchester Institute of Science and Technology. Dr. Bridger also serves on the scientific advisory board of Alectos Therapeutics Inc., a biopharmaceutical company.

Daniel Levitt

Dr. Daniel Levitt, M.D. Ph.D. is Director of the Company since July 2008. Since October 2009, Dr. Levitt has served as Executive Vice President and Chief Medical Officer of CytRx Corporation, a biopharmaceutical research and development company. From January 2007 to February 2009, Dr. Levitt served as Executive Vice President, Research and Development of Cerimon Pharmaceuticals, Inc., a biopharmaceutical company. From 2003 to 2006, Dr. Levitt served as Chief Medical Officer and Head of Clinical and Regulatory Affairs of Dynavax Technologies Corporation, a biopharmaceutical. Dr. Levitt has received ten major research awards and authored or co-authored nearly 200 papers and abstracts. Dr. Levitt holds a B.A. from Brandeis University and an M.D. and a Ph.D. in Biology from the University of Chicago.

Richard Levy

Dr. Richard S. Levy, M.D., is Director of the Company. He is a Senior Advisor at Baker Brothers Investments. Dr. Levy, previously Executive Vice President, Chief Drug Development and Medical Officer at Incyte Corporation, is Board Certified in Internal Medicine and Gastroenterology and received his M.D. from the University of Pennsylvania School of Medicine.

Kelvin Neu

Dr. Kelvin M. Neu, M.D., is Director of the Company. He is a Managing Director of Baker Brothers Investments. Dr. Neu holds an M.D. from the Harvard Medical School-MIT Health Sciences and Technology program, and spent three years in the Immunology Ph.D. program at Stanford University as a Howard Hughes Medical Institute Fellow.

Sean Nolan

Mr. Sean Nolan is Director of the Company Since February 2015. Since February 2013, Mr. Nolan has served as Executive Vice President and Chief Business Officer of InterMune, Inc., a pharmaceutical company. From August 2011 to December 2012, Mr. Nolan served as Vice President and Chief Commercial Officer at Reata Pharmaceuticals Inc., a pharmaceuticals company. From May 2009 to November 2010, Mr. Nolan served as Chief Commercial Officer and President of Lundbeck Inc., the U.S. entity of H. Lundbeck, a Danish pharmaceuticals company. From 2004 to 2009, Mr. Nolan served in a number of executive positions including VP Marketing and Sales Operations, VP CNS Business Unit and VP Global Product Development at Ovation Pharmaceuticals until the company’s acquisition by H. Lundbeck in March, 2009. Mr. Nolan holds a B.A. in Biology from John Carroll University.

Todd Simpson

Mr. Todd E. Simpson is Director of the Company since January 2014. Since October 2005, Mr. Simpson has served as the Chief Financial Officer of Seattle Genetics, Inc., a publicly traded biotechnology company. Previously, Mr. Simpson served from October 2001 to October 2005 as Vice President, Finance & Administration and Chief Financial Officer of Targeted Genetics Corporation, a biotechnology company. From January 1996 to October 2001, Mr. Simpson served as Vice President, Finance & Administration and Chief Financial Officer of Aastrom Biosciences, Inc., a biotechnology company. From August 1995 to December 1995, he served as Treasurer of Integra LifeSciences Corporation, a biotechnology company, which acquired Telios Pharmaceuticals, Inc., in August 1995. From 1992 until its acquisition by Integra, he served as Vice President of Finance and Chief Financial Officer of Telios and in various other finance-related positions. Mr. Simpson currently serves on the executive committee of the board of directors of the Washington Biotechnology and Biomedical Association. Mr. Simpson is a certified public accountant, and from 1983 to 1992 he practiced public accounting with the firm of Ernst & Young LLP. Mr. Simpson received a B.S. in Accounting and Computer Science from Oregon State University.